Because food supplements are not subject to the same pre-market approval requirements as licensed medicines, manufacturers are not required to demonstrate clinical efficacy or safety to the same rigorous standard
Timper K, Del Rio-Martin A, Cremer AL, Bremser S, Alber J, Giavalisco P, et al
Therefore, many proposed mechanisms are subjects of ongoing scientific investigation rather than established clinical findings
D.van GennipM.JakobsenT
Importantly, the FDA labeling for oral semaglutide (Rybelsus) indicates it can increase levothyroxine exposure by approximately 33% when taken together
Le dichiarazioni relative agli integratori alimentari non sono state valutate dallEFSA (Autorit europea per la sicurezza alimentare) e non sono destinate a diagnosticare, trattare, curare o prevenire alcuna malattia o condizione medica